We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Biodegradable Microneedle Patch Automates Tuberculosis Skin Testing

By LabMedica International staff writers
Posted on 04 Sep 2013
A patch comprising biodegradable microneedles has been developed that may replace the classical hypodermic needle tuberculin diagnostic test for tuberculosis.

The standard diagnostic test for tuberculosis (termed the Mantoux technique) is based on an intradermal injection of tuberculin, which is a species-nonspecific glycerol extract of the tubercle bacillus obtained from filtrates of sterilized, concentrated cultures. More...
A person who has been exposed to tuberculosis bacteria is expected to mount an immune response in the skin containing the bacterial proteins. The reaction is read by measuring the diameter of induration (palpable raised, hardened area) across the forearm (perpendicular to the long axis) in millimeters.

However, the standard diagnostic test is difficult to perform, since obtaining a correct diagnosis depends on the hypodermic needle being inserted into the arm of the patient at a precise angle and depth.

Investigators at the University of Washington (Seattle, USA) recently reported development of a technique that promises to be a significant improvement to the Mantoux technique. They created a patch containing biodegradable chitin microneedles. Each needle is 750 micrometers long and is coated with tuberculin solution.

The patch test was evaluated on guinea pigs, and results showed that following insertion of the microneedles, the positive skin reaction associated with having a tuberculosis infection was identical to that obtained when using the standard hypodermic needle test.

"It is like putting on a bandage," said senior author Dr. Marco Rolandi, assistant professor of materials science and engineering at the University of Washington. "As long as the patch is applied on the skin, the test is always delivered to the same depth underneath the skin. With a microneedle test there is little room for user error, because the depth of delivery is determined by the microneedle length rather than the needle-insertion angle. This test is painless and easier to administer than the traditional skin test with a hypodermic needle."

The guinea pig study was published in the August 26, 2013, online edition of the journal Advanced Healthcare Materials.

Related Links:
University of Washington



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.